

# Jesus G Berdeja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9270070/publications.pdf>

Version: 2024-02-01

41  
papers

3,339  
citations

567281

15  
h-index

345221

36  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3353  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciltacabtagene Autoleucl, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	1.6	160
2	A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 226-233.	4.1	5
3	Idecabtagene Vicleucl in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	27.0	1,129
4	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
5	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	2.3	21
6	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 752-765.	0.4	10
7	A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. <i>American Journal of Hematology</i> , 2021, 96, 428-435.	4.1	6
8	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, e000734.		27
9	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	56
10	Practical aspects of building a new immunotherapy program: the future of cell therapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 579-584.	2.5	2
11	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	7.2	45
12	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. <i>American Journal of Hematology</i> , 2019, 94, 794-802.	4.1	10
13	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	27.0	1,130
14	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393.	1.3	11
15	A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 603-603.	1.4	6
16	Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 365-373.	2.5	10
17	An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S240-S241.	0.4	0
18	Twice-weekly ixazomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.5	30

#	ARTICLE	IF	CITATIONS
19	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. Journal of Clinical Oncology, 2018, 36, 8022-8022.	1.6	2
20	Phase I study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. British Journal of Haematology, 2017, 177, 254-262.	2.5	6
21	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood, 2016, 127, 3360-3368.	1.4	89
22	Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 129-138.	0.4	68
23	A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion. Blood, 2016, 128, 4530-4530.	1.4	5
24	Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 670-676.	3.5	82
25	A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts. Blood, 2015, 126, 1825-1825.	1.4	5
26	Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia. Blood, 2015, 126, 3928-3928.	1.4	13
27	A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 911-911.	1.4	10
28	Clinical Utility of High-Throughput and Complimentary Genomic Tumor Profiling in Hematologic Malignancies. Blood, 2015, 126, 1388-1388.	1.4	0
29	A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma. Blood, 2015, 126, 1492-1492.	1.4	1
30	Lorvotuzumab mertansine: antibody-drug-conjugate for CD56 <sup>+</sup> multiple myeloma. Frontiers in Bioscience - Landmark, 2014, 19, 163.	3.0	41
31	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncology, The, 2014, 15, 1503-1512.	10.7	233
32	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood, 2014, 124, 3553-3560.	1.4	56
33	An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia. Blood, 2014, 124, 4422-4422.	1.4	5
34	A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3336-3336.	1.4	0
35	Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2013, 31, 8502-8502.	1.6	5
36	A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology, 2012, 30, TPS8115-TPS8115.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 2461-2461.	1.4	3
38	Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2010, 116, 2799-2799.	1.4	2
39	Blood and Bone Marrow Transplantation for Patients with Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma. , 2006, 131, 251-281.		3
40	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 561-567.	2.0	22
41	New approaches to blood and marrow transplantation for patients with low-grade lymphomas. <i>Current Opinion in Oncology</i> , 2001, 13, 335-341.	2.4	7